These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1981012)

  • 41. [Hypothalamic factors: recent diagnostic and therapeutic advances].
    Gaillard RC
    Schweiz Med Wochenschr; 1987 Aug; 117(34):1270-7. PubMed ID: 2890201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A
    BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract]   [Full Text] [Related]  

  • 43. New molecules and treatment modulation in advanced prostatic cancer.
    Mahler C; Verhelst J; Denis L
    Acta Urol Belg; 1996 May; 64(2):95-8. PubMed ID: 8701825
    [No Abstract]   [Full Text] [Related]  

  • 44. Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma.
    Sciarra A; Bosman C; Monti G; Gentile V; Autran Gomez AM; Ciccariello M; Pastore A; Salvatori G; Fattore F; Di Silverio F
    J Urol; 2004 Nov; 172(5 Pt 1):1775-83. PubMed ID: 15540720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Use of LHRH agonists in the treatment of advanced cancer of the prostate].
    Fretin J
    Arch Esp Urol; 1990; 43(6):647-9. PubMed ID: 2151155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Growth hormone inhibitors in prostate cancer: a systematic analysis.
    Schmid HP; Gregorin J; Altwein JE
    Urol Int; 2008; 81(1):17-22. PubMed ID: 18645266
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth.
    Reubi JC
    Acta Endocrinol (Copenh); 1985 May; 109(1):108-14. PubMed ID: 2860768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers.
    Redding TW; Schally AV
    Prog Clin Biol Res; 1988; 262():217-40. PubMed ID: 2897695
    [No Abstract]   [Full Text] [Related]  

  • 49. New approaches to the therapy of various tumors based on peptide analogues.
    Schally AV
    Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
    Dimopoulos MA; Kiamouris C; Gika D; Deliveliotis C; Giannopoulos A; Zervas A; Alamanis C; Constantinidis C; Koutsilieris M
    Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of somatostatin analogs in the management of prostate cancer.
    Sinisi AA; Rossi V; Prezioso D; Notaro A; Bellastella G; Panza N; Bellastella A; Pasquali D
    J Endocrinol Invest; 2003; 26(8 Suppl):120-4. PubMed ID: 15233227
    [No Abstract]   [Full Text] [Related]  

  • 52. [Somatostatin in breast cancer].
    Frati A; Antoine M; Rodenas A; Gligorov J; Rouzier R; Chéreau E
    Ann Biol Clin (Paris); 2011; 69(4):385-91. PubMed ID: 21896402
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy.
    Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Gentilucci A; Lisi D; Passariello R; Gentile V; Di Silverio F
    Eur Urol; 2008 Mar; 53(3):652-5. PubMed ID: 17316966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advanced breast cancer: response to somatostatin.
    Stolfi R; Parisi AM; Natoli C; Iacobelli S
    Anticancer Res; 1990; 10(1):203-4. PubMed ID: 1970716
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lethal somatostatin analog-induced acute necrotizing pancreatitis in a patient with hormone-refractory prostate cancer.
    Battaglia M; Ditonno P; Palazzo S; Bettocchi C; Garofalo L; Selvaggi FP
    Scand J Urol Nephrol; 2006; 40(5):423-5. PubMed ID: 17060090
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
    Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
    Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer.
    Yagoda A; Petrylak D
    Cancer; 1993 Feb; 71(3 Suppl):1098-109. PubMed ID: 7679039
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Somatostatin analogue treatment of neuroendocrine tumours.
    de Herder WW; van der Lely AJ; Lamberts SW
    Postgrad Med J; 1996 Jul; 72(849):403-8. PubMed ID: 8935599
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.